November 5, 2021
Via: The Medical NewsYounger patients with specific genetic subtypes of non-GCB DLBCL, called MCD and N1, had an exceptional response to the treatment combination. New evidence suggests that adding the targeted therapy ibrutinib (Imbruvica) to a standard chemotherapy regimen can improve how long […]
July 19, 2024
Copyright © 2024. All rights reserved
